Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In re-reading this, I see it may not have come off as intended- I was trying to jokingly give Doug a "dig" about asking someone to repost Mark's update earlier.
So sorry if it wasn't taken that way.
LOL! But, now that I think about it, you've been delegating quite a bit today...hmmmm... :)
Seriously, I don't mind checking but have no idea where to start. Maybe we can get Mongo to check for us.
Texas, I think that it must be a glitch on Scottrade's end. I think if news was coming out and Scottrade added the ".v" symbol, we would've been able to find it on edgar, google news, business wire, etc. by now. Hey, bwdik?
Wonder if it's Franklin?
"the government has appointed an accountant whose position is that of an assistant director"
Just kidding, of course.
That's the bankruptcy scenario I was talking about. It's after a company is coming out of bankrupcty and they're offering new shares. So, no, does not apply here.
"If the company does come out of bankruptcy, there may be two different types of common stock, with different ticker symbols, trading for the same company. One is the old common stock (the stock that was on the market when the company went into bankruptcy), and the second is the new common stock that the company issued as part of its reorganization plan. If the old common stock is traded on the OTCBB or on the Pink Sheets, it will have a five-letter ticker symbol that ends in "Q," indicating that the stock was involved with bankruptcy proceedings. The ticker symbol for the new common stock will not end in "Q". Sometimes the new stock may not have been issued by the company, although it has been authorized. In that situation, the stock is said to be trading "when issued," which is shorthand for "when, as, and if issued." The ticker symbol of stock that is trading "when issued" will end with a "V". Once the company actually issues the newly authorized stock, the "V" will no longer appear at the end of the ticker symbol. Be sure you know which shares you are purchasing, because the old shares that were issued before the company filed for bankruptcy may be worthless if the company has emerged from bankruptcy and has issued new common stock.
I don't know, I can only find two times a .v would be used (one listing a Canadian stock and one when a company was emerging from bankruptcy). Neither apply here, maybe it's a Scottrade symbol? I think some brokers add for things like "news", etc? Please let us know if you find out.
Edit: See that it may have been there all the time. And, fwiw, I checked news and Pacer, nothing new on either.
Yeah, I know nothing about "oil industry standard"...it seems to me, from what I've read, that the transaction did violate the new rules. However, I don't think that the govt will rescind the deal.
Another Starcrest/Addax article:
DPR bid rounds suffer criticism
• Thursday, Nov 30, 2006
The ability of Directorate of Petroleum Resources (DPR) to hold free and fair bid rounds has come under attack following the ripples its recent award of Oil Prospecting License (OPL) 291 to Starcrest, an indigenous oil company, has caused in the oil industry.
Oil business analysts had said that DPR had awarded Starcrest the OPL 291 during a recent bid rounds, but that instead of paying the initial 25 per cent and the subsequent 75 per cent of the bid according to the rule of the game, Starcrest could not but hawked and sold 75 per cent interest to Addax Petroleum, a foreign firm.
The Tide learnt that the consideration for awarding the OPL 291 to Starcrest was in keeping with federal government’s local content policy but that trouble started in the process when Starcrest could not pay in line with the rules but sold the interest to Addax Petroleum, yet DPR looked away as if nothing happened.
The Tide further gathered that the development was threatening to erode the confidence of international investors in Nigeria’s oil and gas industry as the investors had started suspecting a foul play in the conduct of the bid rounds.
The analysts said that lack of confidence would have marred the 2005 bid rounds as major multinational oil companies withdrew their bids at the last minute over what they regarded as lack of transparency in the whole exercise.
In the circumstance, the former director of DPR, Mr. Tony Chukwueke had, however, debunked the allegation when he said that the inability of the multinational oil companies to participate in the bid rounds was not their lack of confidence in the exercise but that their hands were full.
A source from DPR noted that, in spite of the former director’s claim, the multinational firms were still casting aspersions on DPR over the conduct of the bid rounds, especially as it affected the right of first refusal of oil blocks, which signified an automatic ownership claim to the blocks, but which the DPR director explained that the rights were given to such companies which indicated interest to develop the downstream projects.
The source remarked that the operators viewed the DPR policy as one that would not preserve justice and equity, and added that the operators saw it as corruption in the oil industry, the allocation of OPL 291 to Starcrest which sold 75 per cent interest to Addax Petroleum for $90 million.
The corruption view was strong because the operators did not understand why DPR allowed Addax to pay $55 million to federal government as signature bonus and $35 million to Starcrest for rendering no service at all, the source hinted.
The Tide gathered that Peter Ogbonna, the Chief Press Secretary to the Minister of Petroleum Resources had however, defended the process as being right when he claimed that his ministry was satisfied with the manner Addax Petroleum acquired the working interest of OPL 291 as it was in accordance with oil industry standard.
Thanks, Sue! I think my husband would go crazy if I brought another cat into the house, though. He's feeling very bold after hearing Phil's suggestion and is now offering very creative ways to solve this situation. :)
But, I really like the idea of giving the cat it's own space, I'm going to try it. Thanks, again.
Australia Debates Lifting Ban on Cloning Embryos for Research
By Gemma Daley
Nov. 30 (Bloomberg) -- Scientists will be allowed to create human embryo clones for medical research if the Australian government passes news laws, being debated today, to lift a four-year ban.
The Australian lower house is debating a proposal to legalize the creation of human embryos through so-called somatic cell nuclear transfer to aid research into diseases including Parkinson's and multiple sclerosis. The debate is expected to take four days, double the time the House of Representatives discussed the annual budget and Telstra Corp.'s privatization.
If approved, scientists could create embryos with the DNA of a person from stem cells using the same therapeutic cloning technology that produced Dolly the sheep and 10 other animals. Stem cells extracted from such an embryo would be genetically identical to the person donating the DNA, as would tissue such as neurons grown from its stem cells. The research is controversial because it could, in theory, lead to human clones.
``We have to allow people to look to science for answers to cure debilitating and fatal diseases,'' Labor lawmaker Simon Crean told parliament today. ``We have to bring an open mind and honest heart to the debate.''
Lawmakers and interest groups are also divided on the ethics of creating embryos for research and then destroying them after their stem cells have been extracted. President George W. Bush restricted research funding on human embryonic stem cells in 2001, saying he was against the destruction of embryos.
`Sanctity of Life'
``Permitting human embryos for scientific research paves the way for society that disregards life itself,'' said Brian Houston, President of the Assemblies of God in Australia, said in an interview from Sydney today. ``The pursuit of science should never override the sanctity of life.''
Australia allows medical research on spare embryos from assisted reproductive technology, such as in-vitro fertilization (IVF). Australia has held five inquiries into medical research on embryonic cells since 1998. The latest, the Lockhart Review, was released on June 23.
Under existing laws, scientists can apply for a license to use leftover IVF embryos for research. The scientist must have the permission of the woman who created the embryo. Scientists can also use adult stem cells.
Laws prohibit implanting a created embryo clone in a human or animal, importing or exporting a human clone, creating a human embryo by fertilization of a human egg and sperm for anything other than assisted pregnancy, and developing a human or hybrid embryo outside of the woman for more than 14 days.
New Ground
Somatic cell nuclear transfer has been accomplished in numerous animals but not so far in humans. Scientists take a piece of skin from a patient, isolate a cell and remove its nucleus. They then insert that nucleus into an egg cell whose original nucleus has been removed. Under proposed changes, the technique could produce an embryo that is an exact genetic match of the patient and stem cells could be harvested and replicated.
``This will bring us in line with the U.S., Britain, Switzerland, Sweden and Korea,'' Liberal Senator Kay Patterson, the author of the proposed laws, said in an interview in Canberra today. ``The companies from here and overseas will have to adhere to strict guidelines to carry the research out.''
People who break the rules could be jailed for as long as 15 years.
Scientists will have to apply for a license through the Canberra-based National Health and Medical Research Council. The companies may be based elsewhere, but the research must be conducted in Australia and adhere to strict guidelines.
Human Farm?
``These laws will lead to the cloning and farming of human life,'' Nationals party Senator and Catholic Barnaby Joyce, a father of four, said in an interview in Canberra yesterday. ``What this will lead to is developing a pre-born child to three months, taking it out of the womb because it has a perfectly cloned liver, pancreas or cornea and using that to help someone.''
Scientists, including the Australian Stem Cell Center, have lobbied the Australian government to relax the rules around stem cell research and the use of spare human embryos left over from IVF and other assisted reproductive procedures. The existing laws came into effect in 2002.
``I would never forgive myself if I voted against this bill and did not give medical research that extra opportunity to succeed in finding care for some of those terrible diseases which are now incurable,'' Liberal Senator Alan Ferguson said in an interview in Canberra yesterday. Ferguson's daughter was diagnosed with multiple sclerosis 13 years ago.
Advanced Cell, Geron
California's Advanced Cell Technology Inc. and Geron Corp. are the only two publicly traded U.S. companies working to develop medical advances based on human embryonic stem cells, the cells most capable of turning into other types of cells, such as for skin or blood.
Other companies, including Osiris Therapeutics Inc., Genzyme Corp., StemCells Inc., Aastrom Biosciences Inc. and Viacell Inc., are developing treatments using adult stem cells, which are less versatile and less controversial. The enterprises in both camps are all in the research phase and years from having profitable products.
To contact the reporter on this story: Gemma Daley in Canberra at gdaley@bloomberg.net
Last Updated: November 29, 2006 23:25 EST
Thanks for this info...I've been trying for the last hour to really pay attention to the cat...yet, he's pi**ed! He'll sit next to me, then when I try to pet him, he attacks...Not viciously, but enough to show he's mad.
I'll keep trying though...
Thanks for the suggestion, I'll see how that works.
Another question, though. This territorial battle has been going on all day. Earlier I reprimanded the cat in front of the dog and so now the dog is feeling a little better. If I'm holding the cat, then at least the dog will come in the house. But, the cat is NOT happy about me taking "the dog's side", though, I'm really not favoring the dog just trying to keep the cat from clawing her eyes out.
So, now that the cat is angry, will he spray in the house? Again, I know nothing about cats and am not even really sure what this means, other than you don't want it to happen. He is neutered if that makes a difference.
I appreciate anyone's thoughts on this.
Geesh - this is almost as exasperating as raising two kids!
"Ihub braintrust puts in new batteries"...that's a good one.
I saw that "ignores" was causing other problems on the site, but didn't realize it was causing this message to appear, too. Hope that solves the problem!
Seems to be a glitch in the site. Someone posted it earlier on the Q&A board but they didn't "reply" to one of the admin's posts so not sure if they're aware of it. You might want to try posting the info to Meatloaf's board. He's the new programmer(?) here.
http://www.investorshub.com/boards/board.asp?board_id=7106
November 29, 2006 02:00 PM Eastern Time
NYSSA Presents 10th Annual Biotech/Specialty Pharma Conference
Biotech/Specialty Pharma Conference
NEW YORK--(BUSINESS WIRE)--The New York Society of Security Analysts (NYSSA) will present the 10th Annual Biotech/Specialty Pharma Conference on December 12 to 13, 2006.
What does the future have in store for the biotech industry? Don’t miss this chance to hear Michael D. West, PhD, president of Advanced Cell Technology and author of The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Human Aging, discuss the emerging field of stem cell research. Other presentations include companies focused on hormone therapy, drug delivery and treatments for HIV/AIDS and cancer.
The following companies are presenting on day one:
Aradigm Corporation (Nasdaq: ARDM); BioSante Pharmaceuticals, Inc. (AMEX: BPA); CytRx Corporation (Nasdaq: CYTR); DNAPrint Genomics, Inc. (OTCBB: DNAG); DRAXIS Health Inc. (Nasdaq: DRAX; TSX: DAX); DURECT Corporation (Nasdaq: DRRX); Heska Corporation (Nasdaq: HSKA); The Immune Response Corporation (OTCBB: IMNR); Viral Genetics, Inc. (OTCBB: VRAL); and Xechem International, Inc. (OTCBB: XKEM).
The following companies are presenting on day two:
Advanced Cell Technology, Inc. (OTCBB: ACTC); Cleveland BioLabs, Inc. (Nasdaq: CBLI); Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC); EntreMed, Inc. (Nasdaq: ENMD); Neuro-Hitech Pharmaceuticals, Inc. (OTCBB: NHPI); Provectus Pharmaceuticals, Inc. (OTCBB: PVCT); The Quigley Corporation (Nasdaq: QGLY); and XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB).
The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 5, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at
http://www.nyssa.org/Template.cfm?Section=conferences___ seminars&template=/ContentManagement/ContentDisplay.cfm&ContentID=8977
About NYSSA
NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members.
Thanks, DK! That's a great idea!
I've never owned a cat before this one adopted us so I'm clueless when it comes to this species. But, this sounds like it might work. Thanks for the tip!
LOL! Although, my husband would love me to consider this solution, the kids would be heartbroken. :)
I'm having trouble with my pets and I'm hoping someone here can offer some advice.
We just adopted a dog - Border Collie, mix. And, we have an indoor/outdoor cat who's pretty tough. I read that because Border Collie's are herders, you have to immediately teach them that they cannot herd the cat. So, the first day whenever the cat came into the dog's sight, we made the dog sit. Seemed to be working fine.
Well, the next day we were outside and the cat took the dog unaware and pounced at him. Border Collie's have a high startle reflex, and she took off running with the cat chasing her. Since then the cat hides in places so she can pounce at the dog again. The dog is terrified - geesh! I had to literally drag her into the house after she saw the cat come in.
If anyone has any suggestions on how to make the cat stop terrorizing the dog, I'd really appreciate it.
Welllll, nwtf, I actually do believe that there are people that use message boards to try to manipulate the pps. I'm just not one that believes that Crazy does this. :)
TopShelf, sorry, I did lose your point re: whether he was a fortune teller or not. I thought you were saying that because he is a trader he was obviously trying to make the price go down when he made that post. Hope no offense was taken. Glty.
Only my opinion, but just because someone trades and happens to make a prediction, does not mean they are trying to talk the stock down. This whole thing has become convoluted - Crazy made the prediction based on a .31 trade when we were trading higher (.38ish maybe?). His speculation was that it was a signal between the mm's to take it down to this level.
Imo, it was just that, him taking a stab at figuring out what the strange trade meant. Of course, at the time, there were people who suggested he was trying to get shares lower. But there was also discussion about that specific trade.
Again, omi, but Crazy seemed to call them like he saw them, good or bad. That doesn't mean his intent was manipulate the pps.
Impart Media Group Releases Web Portal Content Media Source for Digital Signage and Interactive Kiosks
Posted on : Tue, 28 Nov 2006 13:04:00 GMT | Author : Impart Media Group, Inc.
News Category : PressRelease
SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- Impart(TM) Media Group, Inc. (BULLETIN BOARD: IMMG) , an innovative full service provider of hardware, content, and advertising for digital media networks announced today the formal release of Impart IQ Streams(TM), an easy-to-use, web portal media source and library of premiere infotainment content for digital signage and interactive kiosks networks or applications. As of the launch today, Impart IQ Streams(TM) delivers sports, news, finance, entertainment, music, and weather in motion video, still graphic, flash animation, text, or IPTV formats to media players or to virtually any device via open standard, XML protocols.
The Impart IQ Streams(TM) digital library was conceived as an essential add-on for the Impart IQ(TM) solution, a media platform developed by Impart for digital signage and interactive kiosks. "Impart IQ Streams(TM) is the quintessential repository for digital content," said Impart CTO Todd Weaver. "It tackles three industry needs: first, it automatically delivers the content people want; second, it builds recurring revenues that companies want; and third, it creates stickiness to the branded content that providers want. The Impart IQ Streams(TM) repository has been architected to be technologically agnostic, based on a web services standard, and was specifically designed to target all digital media networks. The Impart IQ Streams(TM) library is our first in a two wave storm surge, adding in the second wave, Impart IQ Ads(TM) in 2007."
By definition, the Impart IQ Streams(TM) digital library represents a private subscription based, web portal service for content provided by a myriad of sources including: Accu-Weather, Quote-Media, YouTube, CNN, RED, NOAA, AHN, AP, and others. As the digital media library expands, more content and future IPTV channels will become available for variety of applications including health and fitness, generalized waiting areas, food and dining, infotainment, shopping, travel and financial applications.
According to Impart's President & COO, Thomas C. Muniz, "Impart IQ Streams(TM) represents the equivalent of RSS feeds or podcasting for digital signage. We will standardize the industry ... first on media content distribution and early next year, on advertising."
Advanced Cell presses on
By David Morrill, Business Writer
Inside Bay Area
Article Last Updated:11/27/2006 05:31:57 PM PST
Robert Lanza is all about science.
He has written numerous textbooks, was part of the team that cloned the first human embryo and is now vice president of research and scientific development with Alameda-based biotechnology company Advanced Cell Technology Inc.
So, when Lanza released a paper in August in the scientific journal Nature about a method where new stem cell lines and therapies could be created without destroying embryos, as a scientist he felt as if he struck gold.
But after an initial positive response, the article received a horde of negative attention. Some felt misled because while the study's method was described, the paper didn't clearly state that ultimately all of the remaining cells were destroyed.
To appease the critics, last week Nature released a second version of the story in which specific clarifications were added to the paper. Among the changes was the phrase, "In this proof of principle study ..." to emphasize that it was a process being illustrated.
Still, the clarification reaffirmed that Advanced Cell's technique was scientifically sound, Lanza said.
Lanza said Monday that it's important to note that the remaining cells were destroyed because the original article was submitted in April and not published until four months later. Lanza believes that the remaining embryonic cells could have continued to be developed, but at the time he did not think that was necessary to prove the study.
"The political forces out here succeeded in creating this uncertainty," Lanza said. "But as a doctor, a scientist and as a human being, I sit here with disbelief that this has become such a controversy."
Initially, the attention the 37-employee company received was positive because both media and fellow scientists felt Advanced Cell Technology had addressed many people's ethical concerns involving human embryonic stem cells.
"The major objection of all human embryonic stem cell methods is you're destroying an embryo, so I was thinking, `Well here we go, now we have a way of doing it without destroying the embryo,"' Lanza said. "We felt we had the solution."
But then came the backlash.
"This is one of those things where joy was suddenly replaced with disbelief by what was going on," said Lanza, who has written a textbook on stem cell research and studied as a student in the lab of polio vaccine developer Jonas Salk.
In September before a Senate subcommittee, Lanza was blasted by Sen. Arlen Specter, R-Pa., who said, "It's a black eye if scientists are making false and inaccurate representations."
Lanza hopes that now, with the new paper, Advanced Cell can put the politics behind it and focus on what he loves, the science of stem cell research.
John McCamant, editor of Medical Technology Stock Letter in Berkeley, would like to see more clinical research from the company because there's not a lot of data investors can latch onto now.
Shares of Advanced Cell Technology are currently trading over-the-counter. On Monday, shares closed at 88 cents, unchanged during the day.
"Without anything in the clinical trial process, it's really difficult to figure out how to value a company like this," McCamant said.
http://www.insidebayarea.com/business/ci_4730149
As far as I've been able to uncover, there is no governing body that mandates an annual (or otherwise) shareholder meeting.
StemCellPatents.com Applauds Blasticon for Issuance of Breakthrough Stem Cell Patent
TORONTO--(BUSINESS WIRE)--StemCellPatents.com congratulates the German biotech company Blasticon Biotechnologische Forschung GmbH for issuance of a US patent, which in the opinion of StemCellPatents.com, may lead to a revolution in stem cell therapeutics.
“We at StemCellPatents.com try to disseminate critical findings in the area of stem cell research. By identifying key discoveries and devising ways to improve upon them, we believe the rate of clinical translation of stem cell sciences can be greatly accelerated,” stated Dr. Zhoahui Zhong, Chairman of StemCellPatents.com.
It appears that the issued US patent # 7,138,275 discloses methods and examples of taking peripheral blood monocytes, de-differentiating them using commonly available cytokines such as M-CSF and IL-3, and redifferentiating them into various tissues such as islets, hepatocytes, or neurons. The patent provides not only morphological, but also phenotypic and functional evidence that cells derived from the “reprogrammed monocyte stem cell” actually are the tissues that they are claimed to be. Since monocytes can be derived in large quantities from peripheral blood, this patent may be used to generate large quantities of patient-specific stem cells so as to avoid the need for allogeneic donors or immune suppression.
“Readers of StemCellPatents.com will quickly see new ways in which the scope of this patent can be broadened by synergizing it with existing patents described on our website. For example, one could use the retrodifferentiation technology described in US patent application #20040199935 which is owned by Advanced Cell Technology, to augment the potency and yield of stem cells generated according to the current patent. Alternatively, one could generate autologous neural cells from monocytes as thought in the # 7,138,275 patent, and administer them for accelerating hematopoietic engraftment according to US Patent # 6,897,060 held by Neurosphere Holdings,” concluded Dr. Zhong.
About StemCellPatents.com
StemCellPatents.com is an informal organization of concerned scientists, lawyers and intellectuals that assembled the only comprehensive index of all issued US stem cell patents: accessible freely as a Beta Version at www.stemcellpatents.com. StemCellPatents.com is not affiliated in any manner with Blasticon Biotechnologische Forschung GmbH and the views presented herein are only those of StemCellPatents.com.
Wellllll, they did pr that they were working with Microsoft but we have no idea to what scale. Anyone else seen more than this?
"According to Impart's Chairman and CEO, Joe Martinez, "While we continue to look closely at the efficacy we of the Network Provider revenue model, we are expanding and accelerating our efforts in selling our proprietary Impart IQ(TM) hardware and interactive media products into major Fortune 500 companies and are focusing on a much shorter path to profitability. We have received orders for over 1,000 Impart IQ(TM) players since May 2006 and expect to engage a number of new clients to complement our existing marquee clients (e.g., Microsoft, AT&T, RediClinic, Bell Canada, Dole and Nordstrom) who are considering mass deployments of our Impart IQ(TM) products, as inherent and scalable technological advantages along with greater audience impact in the out-of-home advertising sector become evident."
Simpson Says He Did Book for Money
By LINDA DEUTSCH 11.22.06, 2:24 PM ET
O.J. Simpson told The Associated Press he participated in the ill-fated "If I Did It" book and interview project for one reason - personal profit, acknowledging that any financial gain was "blood money."
"This was an opportunity for my kids to get their financial legacy," Simpson said in interviews this week with the AP after the book deal was abandoned by its publisher. "My kids understand. I made it clear that it's blood money, but it's no different than any of the other writers who did books on this case."
The book, said to describe how he theoretically would have committed the murders of ex-wife Nicole Brown Simpson and her friend Ronald Goldman, had been scheduled for release Nov. 30 following the airing of a two-part Simpson interview on Fox on Monday and Wednesday.
News Corp., owner of Fox Broadcasting and publisher HarperCollins, canceled the project after a public outcry and objections by advertisers and booksellers.
In a radio interview Wednesday, Simpson said the project was not a confession to the slayings. "I made it clear from the first day I met the writer that I wasn't involved," Simpson said in a telephone interview broadcast on Miami's WTPS-AM. "I said, 'I have nothing to confess.'"
Goldman's family, meanwhile, asked News Corp. to turn over its rights to the now-canceled book and interview, an attorney said Wednesday.
In two AP telephone interviews this week from his Florida home, Simpson declined to say how much of an advance he received for the book but said it was less than the $3.5 million that has been reported. He said the money has already been spent, including some he used to meet his tax obligations.
Simpson said he was convinced the book would have been a best-seller.
"My kids would have been coming into a lot of money," he said, adding he desperately needs the cash because his retirement funds are dwindling.
He also said he deserved the harsh criticism for his role in the project, although he complained that News Corp. owner Rupert Murdoch appears to be getting off easy.
"I'm taking heat and I deserve it," Simpson said. "But Murdoch should not be taking the high road either."
Publisher Judith Regan has portrayed the book as representing "O.J.'s confession," and it reportedly contains a chapter where he explains how he could have committed the killings.
But the former football star says he didn't commit the murders. He said the book was ghostwritten.
"When I saw what he wrote, I said, 'Maybe you did it because they're saying the chapter contains things only the killer would know.' I don't know these things," Simpson said.
Simpson said Wednesday he never spoke to Regan until taping the TV interview.
"In the course of the interview I said, 'This is blood money and I hope nobody reads it,'" Simpson told the AP.
He added, "Everybody who has written a book about this has taken blood money; you can't have selective morality."
Simpson said he was disappointed by Regan's "confession" statement, although he noted, "I thought, 'This lady probably thinks I did it and I didn't.'"
Simpson insisted he did not try to peddle the book to anyone, saying "a guy" he would not identify brought the proposal to one of his family members.
When Regan got involved, he said, he informed her he would not allow the book's publication if it contained any graphic images.
"I told her I will not OK anything if you describe anyone cutting or stabbing," he said.
Asked how he felt about the effect the book would have on the victims' families, Simpson expressed bitterness toward Goldman's father, Fred, who has denounced Simpson as a liar and murderer.
Simpson was acquitted of murder in 1995 but was later found liable for the killings in a wrongful-death suit filed by the Goldman family. Simpson has failed to pay the $33.5 million judgment against him in that case, and his pensions and his Florida home cannot be seized.
He said Fred Goldman has helped drain his finances with "frivolous lawsuits," including one he brought recently attempting to deprive Simpson of the commercial rights to his name. Although Simpson prevailed in court he said he spent $17,000 in legal fees.
Fred Goldman's attorney, Jonathan G. Polak, said Goldman wants the rights to the material to ensure that all copies are destroyed and that News Corp. doesn't sell the rights to "some sleazy cable pay-per-view operation or video site."
After Murdoch canceled the book and interview, News Corp. subsidiary HarperCollins said all copies of the book will be destroyed.
Polak acknowledged that it was likely that copies of the book or portions of the interview would be leaked and appear in other media. But he said owning the rights might allow him to go to court and ensure any money from the projects goes to the families of the victims.
A call to a News Corp. seeking comment was not returned.
Simpson, 59, said his NFL pension pays only $1,700 a month and the private pension he amassed during the days when he was a TV pitchman and sports commentator is being halved next month because he's had to dip into the principal.
Although he knew the project would bring an avalanche of negative publicity, Simpson said he was willing to face it "if that's what it took."
"You guys are going to dog me no matter what," he told a reporter.
Despite his financial troubles, Simpson indicated he wasn't entirely unhappy the project was abandoned.
"I feel like a man who's had the weight of the world taken off me," he said.
Associated Press writers Robert Jablon in Los Angeles and Curt Anderson in Miami contributed to this report.
November 22, 2006
Journal Clarifies Stem-Cell Report
By NICHOLAS WADE
The scientific journal Nature today issued a clarification of a recent report that human embryonic stem cells could be derived without harm to the embryo, but the journal affirmed the report’s scientific validity.
The finding, by Robert Lanza and colleagues at Advanced Cell Technology in Worcester, Mass., caused a stir when it was published online in August, because it seemed to undercut the argument of stem-cell opponents that working with the cells necessarily means a potential human life has to be destroyed.
Dr. Lanza’s approach is made possible by pre-implantation genetic diagnosis, a test used in fertility clinics. In the test, one cell is removed for genetic testing when the embryo has reached the eight-celled stage, apparently doing the embryos no harm. Embryos tested in this way have been implanted and have resulted in the births of apparently healthy children.
Dr. Lanza showed that the one removed cell can be used to generate the embryonic stem cells used in research. The usual method for obtaining them involves a somewhat more advanced embryo, which is destroyed in the process.
Dr. Lanza’s article appears in the printed issue of the journal dated Thursday, along with itemized changes that have been made in the text, as well as an addendum by Dr. Lanza and his colleagues.
The changes spell out issues that were misunderstood or misstated at the time, including in an early Nature press release. Among them was that although Dr. Lanza said others could use his method to avoid destroying embryos, he himself had destroyed those used in his experiments, by using many cells from each rather than just one. Had he taken a single cell from each eight-celled embryo, a much larger number would have been needed — and eventually destroyed.
Dr. Ritu Dhand, Nature’s chief biology editor, said the sole purpose of the clarification was to make the article easier to understand. “There was nothing either scientifically or technically wrong with the paper,” she said. Dr. Dhand added that the journal had the article reviewed by experts a second time, “just to be sure that everything was as it should be.”
It is too soon for other laboratories to have repeated Dr. Lanza’s work, the acid test for new scientific findings. Dr. Lanza said that he had just finished training a team from the University of California, San Francisco, in how to use his technique, and that he expected visitors from four other laboratories.
Dr. Richard Doerflinger, a spokesman for the U.S. Conference of Catholic Bishops, said it was still unproved that stem cells could be derived from a single blastomere, or cell from the very early stages of embryo development, without harming the embryo. The bishops’ conference opposes embryonic stem-cell research.
http://www.nytimes.com/2006/11/22/science/23stemcnd.html?ei=5094&en=13d6158df8d9e8b1&hp=&...
DPR Director, Chukwueke Redeployed
Daily Champion (Lagos)
NEWS
November 20, 2006
Posted to the web November 21, 2006
By Sopuruchi Onwuka
Lagos
THE crisis rocking the Ministry of Petroleum Resources over the award of oil block in the juicy oil prospecting lease (OPL) 291 has finally led to redeployment of Mr Tony Chukwueke from the Department of Petroleum Resources back to the Ministry as Technical Assistant to the minister.
In his place at DPR is placed an Acting Director, Mrs Chidima Njoku, to run the affairs of the agency that regulates the industry and administers the nation's oil blocks for exploration and production.
Contrary to media reports that Mr Chukwueke was placed on technical suspension for impropriety in the award of deepwater OPL 291 to Starcrest Energy, our sources in Abuja said Mr Chukwueke was never suspended.
The shake up in DPR followed allegations of breach of due process in the award of the block which is close to the Chevron operated billion barrel Agbami field the development of which is currently under project stages.
Mr Tony Chukwueke, a world class technocrat with the pedigree of a quintessential Shell man, was caught in the wed of political intrigues in award of oil blocks during the 2006 mini bid round organised for strategic investors in the nation's economy.
Sources in the ministry who are privy to power game that led to the award of the block to Starcrest Energy said the redeployment of Mr Chukwueke to the minister's office was an indication that he is not found culpable in the flawed deal.
OPL 291 was one of the 18 blocks offered to strategic investors in an open bid to investors all of whom had right of first refusal in preferred oil blocks.
At the end of the process, OPL 291 did not receive any bid and had to be put forward.
Swiss multinational, Addax Petroleum, October 23, announced a farm in into the block upon an agreement with Starcrest Energy, raising questions on when and how the block was awarded to the indigenous company.
Our sources said the subsequent production sharing contract between the consortium and Nigerian National Petroleum Coporation (NNPC) indicated strongly that the deal was directed by the industry.
Both DPR and NNPC are the main parastatals of the Ministry of Petroleum Resources currently in the presidency.
Addax stated in a published statement that its consortium with Starcrest Energy would meet the government objectives in the bid arrangement by paying some $55 million signature bonus on the block and commit another $75 million to stipulated work programme.
It also said it would sink substantial investment in independent power projects in line with government's target of commercializing gas resources and boosting power generation in the country.
LOL! To be honest, this is the very first time I could even guess what one of his posts meant.
And, very glad about OJ's book.
Excerpt of new article:
"More casualties are however expected to result from the Addax/Starcrest OPL 291 debacle, as the source also disclosed yesterday that the permanent secretary in the ministry, and the Minister of States Dr Edmound Daukoru may also have their job threatened.
The source said Minister of state and permanent Secretary may be affected because the scaked Chukwueke could not have awarded the oil block without the approval of the Minister.
http://www.thisdayonline.com/nview.php?id=63748
O.J. Simpson book, TV special canceled
Chairman Rupert Murdoch says project was ‘ill-considered’
The Associated Press
Updated: 4:20 p.m. ET Nov 20, 2006
NEW YORK - After a firestorm of criticism, News. Corp. said Monday that it has canceled the O.J. Simpson book and television special “If I Did It.”
“I and senior management agree with the American public that this was an ill-considered project,” said Rupert Murdoch, News Corp. chairman. “We are sorry for any pain that his has caused the families of Ron Goldman and Nicole Brown Simpson.”
A dozen Fox affiliates had already said they would not air the two-part sweeps month special, planned for next week before the Nov. 30 publication of the book by ReganBooks. The publishing house is a HarperCollins imprint owned — like the Fox network — by News Corp.
In the projects, Simpson speaks in hypothetical terms about how he would have committed the 1994 slayings of his ex-wife Nicole and her friend Goldman.
Relatives of the victims have lashed out at the now scuttled publication and broadcast plans.
“He destroyed my son and took from my family Ron’s future and life. And for that I’ll hate him always and find him despicable,” Fred Goldman told ABC last week.
The industry trade publication Broadcasting & Cable editorialized against the show Monday, saying “Fox should cancel this evil sweeps stunt.”
One of the nation’s largest superstore chains, Borders Group Inc., said last week it would donate any profits on the book to charity.
Simpson was acquitted in 1995 of murder in a case that became its own television drama. The former football star and announcer was later found liable for the deaths in a wrongful death lawsuit filed by the Goldman family.
Judith Regan, publisher of “If I Did It,” said she considered the book to be Simpson’s confession.
The television special was to air on two of the final three nights of the November sweeps, when ratings are watched closely to set local advertising rates. It has been a particularly tough fall for Fox, which has seen none of its new shows catch on and is waiting for the January bows of “American Idol” and “24.”
The closest precedent for such an about-face came when CBS yanked a miniseries about Ronald Reagan from its schedule in 2003 when complaints were raised about its accuracy. The Reagan series was seen on its sister premium-cable channel, Showtime, instead.
One station manager who had said he wasn’t airing the special said he was concerned that whether or not Simpson was guilty, he’d still be profiting from murders.
“I have my own moral compass and this was easy,” said Bill Lamb, general manager of WDRB in Louisville.
For the publishing industry, the cancellation of “If I Did It” was an astonishing end to a story like no other. Numerous books have been withdrawn over the years because of possible plagiarism, most recently Kaavya Viswanathan’s “How Opal Mehta Got Kissed, Got Wild, and Got a Life,” but a book’s removal simply for objectionable content is virtually unheard of.
Sales had been strong, but not sensational. “If I Did It” cracked the top 20 of Amazon.com last weekend, but by Monday afternoon, at the time its cancellation had been announced, the book had fallen to No. 51.
I think he is referring to Waziri who was a partner in the company listed in the article posted by Pappin re: Seacrest. Awhile ago, Wheresthefire, asked Oliphant if his predictions had anything to do with this guy. Oliphant responded yes. (Apparently Waziri was in the railroad business prior to his death.)
So, my interpretation is that Oliphant is suggesting some sort of pressure (political?) is being exerted on Offor to accept some sort of deal. I think Oliphant is hypothesizing that the relationship with Waziri and the recent turmoil over Starcrest will be the catalyst Offor needs to accept a deal.
BWDIK? And, really can't believe I'm trying to interpret one of these riddles. :)
Well, there's alot of posters on Raging Bull who have been around for awhile.
I have no idea if mgmt reads this board, but would hope not. :)
But, as we just learned on the ERHE board without a Form 4, these have not necessarily been sold, correct? All of the 144's we've seen lately just mean they have registered to sell and have 90 days to do so, right? And, they don't have to actually file the Form 4 until 12/10 if they have sold.
Anyone, if I have this wrong, I'd appreciate it hearing it. Tia.
MrKush, here's an opportunity to have all your questions answered:
Impart Media Group Announces Third Quarter Earnings Webcast
Friday November 17, 6:04 pm ET
Management to Provide Fourth Quarter 2006 and Fiscal Year 2007 Revenue Guidance
SEATTLE, Nov. 17 /PRNewswire-FirstCall/ -- Impart(TM) Media Group, Inc. (OTC Bulletin Board: IMMG - News), an innovative full service provider of hardware, content, and advertising for digital media networks, announced today that company management will be conducting an audio webcast on Tuesday, November 21 at 4:30 EST to review the third quarter financials and update investors on company developments.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060214/SFTU169LOGO )
Management will give revenue guidance for the fourth quarter of 2006 and fiscal year 2007, along with a discussion on the progress made in the recently announced deployments of the Impart IQ Box(TM) digital media network platform. The conference call will review the financial metrics of the Impart IQ Box(TM) and will include a discussion on the business initiatives and increase in revenue of E&M Advertising (Impart Media Advertising), Impart's direct response business unit.
Investors are encouraged to submit questions, to be included in the presentation by management, to Rick Lutz, Investor Relations for Impart Media Group, at LCGroup@mindspring.com or call 404-261-1196.
The audio webcast will be accessible by dialing 641-297-5400, the access code is 73210. During the live, one-way conference call, management will also monitor and screen questions in real time. Send questions, during the call, to question@impartmedia.com. The audio webcast will be archived on the corporate website ( www.impartmedia.com ) for a period of ninety (90) days.
Source: Impart Media Group, Inc.
CONTACT:
Rick Lutz, LC Group
404-261-1196 or LCGroup@mindspring.com
Andrew Hellman, CEOcast, Inc.
212-732-4300
Not crazy about anything management's doing these days.
C O R R E C T I O N -- Impart Media Group, Inc./
Friday November 17, 11:59 am ET
Impart Media Group's E&M Advertising, and International Media Partners, corrects the October 10, 2006 press release over PR Newswire announcing their handling of a membership acquisition campaign for Community Health Plan. The referred to agreement is exclusive to the client's Medicare line of business, was done without approval of the client, and is strictly against the client's policy with all vendors. Impart Media Group's E&M Advertising, as well as International Media Partners, sincerely apologize for any inconvenience this has caused.
CONTACT: Rick Lutz of LC Group, +1-404-261-1196, or LCGroup@mindspring.com; or Andrew Hellman of CEOcast, Inc., +1-212-732-4300
Here's another article re: Starcrest:
http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061117:MTFH37392_2...